DNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ginkgo Bioworks Holdings Inc (DNA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The company is facing significant financial challenges, insider selling, and a lack of positive catalysts. While the technical analysis shows some bullish indicators, the overall sentiment and fundamentals suggest caution.
The MACD histogram is positive at 0.219 and expanding, indicating bullish momentum. The RSI is at 77.223, which is in the neutral zone but nearing overbought territory. Moving averages are converging, showing no clear trend. Key resistance levels are at 7.973 and 8.472, while support levels are at 6.357 and 5.858. The stock has a 90% chance of a 6.44% increase in the next month but is expected to decline slightly in the next day and week.
No significant positive catalysts identified. The MACD and short-term technical indicators show some bullish momentum.
Insider selling has increased by 74194.76% over the last month. Analysts have downgraded the price target from $9 to $5 and maintain a Sell rating. The company divested its biosecurity business, limiting its guidance to cash burn. Financial performance shows a significant drop in revenue (-56.39% YoY) and gross margin (-22.52% YoY).
In Q3 2025, revenue dropped by 56.39% YoY to $38.84 million. Net income improved by 43.18% YoY but remains negative at -$80.76 million. EPS increased to -1.45, up 34.26% YoY. Gross margin fell to 67.04%, down 22.52% YoY, indicating declining profitability.
BTIG analyst Mark Massaro lowered the price target from $9 to $5 and maintains a Sell rating. The analyst expressed concerns about the company's limited guidance and the need for greater visibility into its progress in building and monetizing autonomous labs.
